[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100497929":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":13,"centralContacts":18,"locations":25,"responsibleParty":56,"collaborators":7,"id":59,"slug":7,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":7,"eligibilityCriteria":64,"healthyVolunteers":60,"sex":65,"minAge":66,"maxAge":7,"enrollmentInfo":67,"targetDuration":70,"studyType":71,"phases":7,"briefSummary":72,"conditions":73,"keywords":7,"overallStatus":28,"whyStopped":7,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"Hospital Universitari de Bellvitge","OTHER",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"PROCEDURE","Target Axillary Dissection","TAD after neoadjuvant chemotherapy and subsequent axillary lymph node dissection",[14],{"name":15,"affiliation":16,"role":17},"amparo Garcia-Tejedor, MDPhD","Instituto de Investigación Biomédica de Bellvitge (IDIBELL)","PRINCIPAL_INVESTIGATOR",[19],{"name":20,"role":21,"phone":22,"phoneExt":23,"email":24},"Amparo García-Tejedor, MDPhD","CONTACT","0034-932607702","2812","agarciat@bellvitgehospital.cat",[26,44],{"facility":27,"status":28,"city":29,"state":30,"zip":31,"country":32,"countryCode":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"Hospital de Bellvitge","RECRUITING","L'Hospitalet de Llobregat","Barcelona","08907","Spain","ES",{"type":35,"coordinates":36},"Point",[37,38],2.10028,41.35967,{"lat":38,"lon":37},[41],{"name":42,"role":21,"phone":43,"phoneExt":7,"email":24},"Amparo Garcia-Tejedor, MDPhD","0034-660223417",{"facility":45,"status":28,"city":30,"state":7,"zip":46,"country":32,"countryCode":33,"cosmosGeoPoint":47,"geoPoint":51,"contacts":52},"Hospital Clínico y Provincial de Barcelona","08036",{"type":35,"coordinates":48},[49,50],2.15899,41.38879,{"lat":50,"lon":49},[53],{"name":54,"role":21,"phone":7,"phoneExt":7,"email":55},"Isaac Cebrecos, MD","CEBRECOS@clinic.cat",{"type":17,"investigatorFullName":57,"investigatorTitle":58,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"Amparo Garcia-Tejedor","Clinical Professor","100497929",false,"NCT05763641","TAD After Chemotherapy in Locally Advanced Breast Cancer","Target Axillary Dissection After Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer","Inclusion Criteria:\n\n* Axillary lymph node metastasis proven by cytology\n* Clinical or radiological N2a (at least 4 suspicious lymph nodes on axillary ultrasound at diagnosis)\n* Extensive T4 subsidiary to axillary lymphadenectomy according to current clinical criteria\n* Neoadjuvant chemotherapy\n\nExclusion Criteria:\n\n* cN3 verified by imaging tests\n* N2 due to internal mammary involvement (N2b).\n* Tumors whose surrogate molecular subtype is luminal A.\n* Patients undergoing neoadjuvant endocrine therapy\n* Patients with local recurrences and metastatic tumors.","ALL","18 Years",{"count":68,"type":69},162,"ESTIMATED","3 Years","OBSERVATIONAL","This is an observational study to validate target axillary dissection (TAD) in locally advanced tumors (cN2 and\u002For cT4).",[74,75,76],"Sentinel Lymph Node","Breast Cancer","Locally Advanced","2025-09-08",{"date":79,"type":80},"2025-09-10","ACTUAL",{"date":82,"type":80},"2021-02-01",{"date":84,"type":69},"2026-06-01",{"name":5,"class":6},2]